Oarsman Capital’s Vertex Pharmaceuticals VRTX Stock Holding History

Oarsman Capital’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2.23M	Buy	4,983 +193	+4%	+$90K	0.28%	59
2025 Q4	$2.17M	Buy	4,790 +74	+2%	+$31.9K	0.28%	62
2025 Q3	$1.85M	Buy	4,716 +329	+7%	+$137K	0.26%	69
2025 Q2	$1.95M	Buy	4,387 +45	+1%	+$20.7K	0.31%	62
2025 Q1	$2.11M	Buy	4,342 +176	+4%	+$82K	0.38%	56
2024 Q4	$1.68M	Buy	4,166 +43	+1%	+$19.9K	0.29%	66
2024 Q3	$1.92M	Sell	4,123 -953	-19%	-$458K	0.35%	59
2024 Q2	$2.38M	Buy	5,076 +146	+3%	+$63.4K	0.52%	38
2024 Q1	$2.06M	Sell	4,930 -611	-11%	-$258K	0.49%	42
2023 Q4	$2.25M	Buy	5,541 +648	+13%	+$239K	0.6%	41
2023 Q3	$1.7M	Buy	4,893 +86	+2%	+$30.1K	0.71%	35
2023 Q2	$1.69M	Buy	4,807 +852	+22%	+$287K	0.74%	37
2023 Q1	$1.25M	Buy	3,955 +928	+31%	+$278K	0.58%	45
2022 Q4	$874K	Buy	3,027 +865	+40%	+$264K	0.45%	69
2022 Q3	$626K	Buy	+2,162	New	+$622K	0.34%	81

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Oarsman Capital's VRTX Position: Q1 2026 in Review

Oarsman Capital increased its Vertex Pharmaceuticals (VRTX) stake by 4% in Q1 2026, buying an estimated $90K and bringing the position to 4,983 shares worth $2.23M. The position accounts for 0.28% of the portfolio, ranked #59.

Oarsman Capital first reported a position in VRTX in Q3 2022 and has held it in 15 quarters since. The position peaked at $2.38M in Q2 2024. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

Oarsman Capital held 4,983 shares of Vertex Pharmaceuticals worth $2.23M as of Q1 2026.
Oarsman Capital bought 193 Vertex Pharmaceuticals shares in Q1 2026, an estimated $90K.
Vertex Pharmaceuticals made up 0.28% of Oarsman Capital's portfolio in Q1 2026, its #59 holding.
Oarsman Capital first reported a position in Vertex Pharmaceuticals in Q3 2022 and has held it in 15 quarters since.
Oarsman Capital's Vertex Pharmaceuticals position peaked at $2.38M in Q2 2024.
1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Oarsman Capital's 13F filing for Q1 2026, filed 28 Apr 2026.